Skip to main content
SpringerLink
Log in

First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies. This screening is done by a combination of two biochemical markers i.e. serum free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT) thickness at 11 + 0–13 + 6 weeks of gestation. A beneficial consequence of screening is the early diagnosis or trisomies 21, 18 and 13. At 11 + 0–13 + 6 weeks, the relative prevalence of trisomies 18 and 13 to trisomy 21 are found to be one to three and one to seven, respectively. All three trisomies are associated with increased maternal age, increased fetal NT and decreased PAPP-A, but in trisomy 21 serum free β-hCG is increased whereas in trisomies 18 and 13 free β-hCG is decreased.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999;13:167–70.

    Article  PubMed  CAS  Google Scholar 

  2. Wilson RD. Amended Canadian Guideline for prenatal diagnosis (2005) change to 2005—techniques for prenatal diagnosis. SOGC Clinical Practice Guidelines, No. 168, November 2005. J Obstet Gynaecol Can. 2005;27:1048–54.

    PubMed  CAS  Google Scholar 

  3. Bindra R, Liao VHA, Spencer K, Nicolaides KH. One stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol. 2002;20:219–25.

    Article  PubMed  CAS  Google Scholar 

  4. Nicolaides KH. Screening for fetal aneuploides at 11 to 13 weeks. Prenat Diagn. 2011;1(31):7–15.

    Article  Google Scholar 

  5. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–7.

    Article  PubMed  Google Scholar 

  6. Nicholas JW, Wayne JH, Allan KH. Antenatal screening for Down’s syndrome with the quadruple test. Lancet. 2003;361(9360):835–6.

    Article  Google Scholar 

  7. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down’s syndrome published erratum appears in. J Med Screen. 1998;5:110.

    Google Scholar 

  8. Petrovic I, Marina D, Juan CK. The role of pregnancy associated plasma protein –A (PAPP-A) in the identification of coronary artery disease activity. Acta Fac Med Naissensis. 2007;24(4):183–8.

    Google Scholar 

  9. Fialova L, Malbohan IM. Pregnancy-associated plasma protein-A (PAPP-A): theoretical and clinical aspects. Bratisl Lek Listy. 2002;103:194–205.

    PubMed  CAS  Google Scholar 

  10. Overgaard MT, Oxvig C, Christiansen M, Lawrence JB, Conover CA, Gleich GJ. Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and non reproductive tissues. Biol Reprod. 1999;61:1083–9.

    Article  PubMed  CAS  Google Scholar 

  11. Overgaard MT, Boldt HT, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276:21849–53.

    Article  PubMed  CAS  Google Scholar 

  12. Qin Q-P, Kokkala S, Lund J, Tamm N, Voipio-Pulkki LM, Pettersson K. Molecular distinction of circulating pregnancy-associated plasma protein-A in myocardial infarction and pregnancy. Clin Chem. 2005;51:75–83.

    Article  PubMed  CAS  Google Scholar 

  13. Overgaard MT, Sorensen ES, Stachowiak D, Boldt HB, Kristensen L, Sottrup-Jensen L, et al. Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein disulfide structure and carbohydrate attachment sites. J Biol Chem. 2003;278:2106–17.

    Article  PubMed  CAS  Google Scholar 

  14. Oxvig C, Sand O, Kristensen T, Kristensen L, Sottrup-Jensen L. Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. Biochim Biophys Acta. 1994;1201:415–23.

    Article  PubMed  Google Scholar 

  15. Oxvig C, Haaning J, Hojrup P, Sottrup-Jensen L. Location and nature of carbohydrate groups in proform of human major basic protein isolated from pregnancy serum. Biochem Mol Biol Int. 1994;33:329–36.

    PubMed  CAS  Google Scholar 

  16. Handschuh K, Guibourdenche J, Guesnon M, Laurendeau I, Evain-Brion D, Fournier T. Modulation of PAPP-A expression by PPARgamma in human first trimester trophoblast. Placenta. 2006;27(Suppl A):S127–34.

    Article  PubMed  Google Scholar 

  17. Overgaard MT, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M, Gleich GJ, et al. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem. 2000;275(40):31128–33.

    Article  PubMed  CAS  Google Scholar 

  18. Bischof P, DuBerg S, Herrmann W, Sizonenko PC. Pregnancy-associated plasma protein-A (PAPP-A) and hCG in early pregnancy. Br J Obstet Gynaecol. 1981;88:973–5.

    Article  PubMed  CAS  Google Scholar 

  19. Bischof P, Amandruz M, Weil-Franck C, Baeriswyl JP, Weil A, Hermann WL, et al. The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies. Arch Gynecol. 1984;236:93–8.

    Article  PubMed  CAS  Google Scholar 

  20. Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17:10–8.

    Article  PubMed  CAS  Google Scholar 

  21. Peterson SE, Simhan HN. First-trimester pregnancy-associated plasma protein A and subsequent abnormalities of fetal growth. Am J Obstet Gynecol. 2008;198(5):43–5.

    Google Scholar 

  22. Gagnon A, Douglas RW. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918–32.

    PubMed  Google Scholar 

  23. Santolaya-Forgas I, Leon JAD, Cullen Hopkins R, Castracane VD, Kauffman RP, Sifuentes GP. Low pregnancy-associated plasma protein-A at 10 + 1 to 14 + 6 weeks of gestation and a possible mechanism leading to miscarriage. Fetal Diagn Ther. 2004;19:456–61.

    Article  PubMed  CAS  Google Scholar 

  24. Brizot ML, Hyett JA, Mckie AT, Bersinger NA, Farzaneh F, Nicolaides KH. Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies. Placenta. 1996;17:33–6.

    Article  PubMed  CAS  Google Scholar 

  25. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987;7:623–30.

    Article  PubMed  CAS  Google Scholar 

  26. Banerjee P, Fazleabas AT. Extragonadal actions of chorionic gonadotropin. Rev Endocr Metab Disord. 2011;12(4):323–32.

    Article  PubMed  CAS  Google Scholar 

  27. Ulf-Håkan S, Aila T, Henrik A, Leena V. The classification, functions and clinical use of different isoforms of hCG. Hum Reprod Update. 2006;12(6):769–84.

    Article  Google Scholar 

  28. Trenti T, Aloe R, Cervellin G, Lippi G. Human chorionic gonadotropin in pregnancy diagnostic. Clin Chim Acta. 2011;412(17–18):1515–20.

    PubMed  Google Scholar 

  29. Fernando MR, Donato D, Felice P. Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocrine. 2006;23(2):230–57.

    Google Scholar 

  30. Butler SA, Iles RK. The free monomeric beta subunit of human chorionic gonadotrophin (hCG beta) and the recently identified homodimeric beta–beta subunit (hCG beta beta) both have autocrine growth effects. Tumour Biol. 2004;25:18–23.

    Article  PubMed  CAS  Google Scholar 

  31. Eldar-Geva T, Hochberg A, deGroot N, Weinstein D. High maternal serum chorionic gonadotropin level in Downs’ syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts. J Clin Endocrinol Metab. 1995;80:3528–31.

    Article  PubMed  CAS  Google Scholar 

  32. Oberweis D, Gillerot Y, Koulischer L, Hustin J, Philippe E. The placenta in trisomy in the last trimester of pregnancy. J Gynecol Obstet Biol Reprod. 1993;12:345–9.

    Google Scholar 

  33. Cowans NJ, Stamatopoulou A, Hellström J, Mäkelä MM, Spencer K. PAPP-A and free ss-hCG stability in first trimester serum using PerkinElmer AutoDELFIA and DELFIA Xpress systems. Prenat Diagn. 2010;30(2):127–32.

    Article  PubMed  CAS  Google Scholar 

  34. Cruz J, Cruz G, Minerkawa R, Mazi N, Nicolaides KH. Effect of temperature on free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A concentration. Ultrasound Obstet Gynecol. 2010;36:141–6.

    Article  PubMed  CAS  Google Scholar 

  35. Schulte-Valentin M, Schindler H. Non-echogenic nuchal oedema as a marker for trisomy 21 screening. Lancet. 1992;339:1053.

    Article  Google Scholar 

  36. Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester fetal nuchal translucency: problems with screening the general population. J Obstet Gynaecol. 1995;102:381–5.

    Article  CAS  Google Scholar 

  37. Karl OK, Dave W, Caalina V, Nerea M, Nicolaides KH. Screening for trisomy 21, 18 and 13 by maternal age, fetal NT, fetal heart rate, free beta hCG and PAPP-A. Hum Reprod. 2008;23(9):1968–75.

    Article  Google Scholar 

  38. Hyett JA, Moscoso G, Nicolaides K. Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses. Am J Med Genet. 1997;69:207–16.

    Article  PubMed  CAS  Google Scholar 

  39. von Kaisenberg CS, Nicolaides KH, Brand-Saberi B. Lymphatic vessel hypoplasia in fetuses with Turner syndrome. Hum Reprod. 1999;14:823–6.

    Article  Google Scholar 

  40. Hyett JA, Sebire NJ, Snijders RJ, Nicolaides KH. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol. 1996;7:101–3.

    Article  PubMed  CAS  Google Scholar 

  41. Khalil Asma, Pandya Pranav. Screening for Down syndrome. J Obstet Gynecol India. 2006;56(3):205–11.

    CAS  Google Scholar 

  42. Spencer K, Heath V, El-Sheikhah A, Ong CYT, Nicolaides KH. Ethnicity and need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of oriental Asian and Afro-Caribbean population. Prenat Diagn. 2005;25:365–9.

    Article  PubMed  CAS  Google Scholar 

  43. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol. 2008;31:493–502.

    Article  PubMed  CAS  Google Scholar 

  44. Wright D, Spencer K, Kagan KO, Torring N, Petersen OB, Christou A, et al. First-trimester combined screening for trisomy 21 at 7–14 weeks gestation. Ultrasound Obstet Gynecol. 2010;36:404–11.

    Article  PubMed  CAS  Google Scholar 

  45. Tul N, Spencer K, Noble P, Chan C, Nicolaides KH. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn. 1999;19:1035–42.

    Article  PubMed  CAS  Google Scholar 

  46. Spencer K, Tul N, Nicolaides KH. Maternal serum free beta hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn. 2000;20:390–4.

    Article  PubMed  CAS  Google Scholar 

  47. Borrell A, Casals E, Fortuny A, Farre MT, Gonce A, Sanchez A, et al. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages: an interventional study. Prenat Diagn. 2004;24:541–5.

    Article  PubMed  Google Scholar 

  48. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008;31:618–24.

    Google Scholar 

  49. Bernd E, Glaubitz Ralf. First-trimester screening: an overview. J Histochem Cytochem. 2005;53(3):281–3.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SRL Diagnostics, Fortis Healthcare Enterprise, Clinical Biochemist, 64, Al Razi Unit 1007, Block A, P.O. Box 505143, Dubai Health Care City, United Arab Emirates

    S. Shiefa, M. Amargandhi, J. Bhupendra, S. Moulali & T. Kristine

Authors
  1. S. Shiefa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Amargandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Bhupendra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Moulali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Kristine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Shiefa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shiefa, S., Amargandhi, M., Bhupendra, J. et al. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome. Ind J Clin Biochem 28, 3–12 (2013). https://doi.org/10.1007/s12291-012-0269-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-012-0269-9

Keywords

Search

Navigation